Kevin Kabler focuses his practice on building and managing patent portfolios for companies and institutions in the life sciences industry in the fields of immuno-oncology, antibodies, personalized medicine, vaccines, genetics, biologics, RNAi, stem cells, and immunotherapy. He provides strategic patent counseling and due diligence to his clients at all stages of the business cycle, evaluating risks from third-party patents and assisting in efforts to reduce identified risks, as well as prepares and prosecutes domestic and international patent applications. Kevin also advises investors in assessing the competitive landscape, technology and intellectual property assets and risks associated with target investments.
Kevin has particularly deep technical and legal experience in the fields of immuno-oncology and immunotherapy. Kevin began his hands-on laboratory work in 2002 studying methods of using checkpoint inhibitors within professional antigen presenting cells for use in cancer vaccines. This work resulted in Kevin being a named inventor on multiple patents and a lead author on numerous scientific papers in leading peer-reviewed journals including Nature Medicine and Nature Biotechnology. In his legal career, Kevin has deepened his expertise in immuno-oncology and immunotherapy by counseling leading companies whose technologies range from antibodies to personalized cancer vaccines on the protection and exploitation of their IP and business in the market.
Kevin is also focused on technology that sits at the nexus between traditional biological and medical research and data science. He is a co-founder of a Fenwick working group with Andrew Whitehead that is rapidly iterating on how to improve patents written in this space to successfully navigate the shifting, modern legal landscape that has significantly impacted what subject matter is deemed eligible for patenting.
Kevin began his career at Fenwick & West as a patent agent in 2007. Prior to joining Fenwick & West, Kevin was a postdoctoral fellow in the laboratory of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.
- A More Consistent USPTO Approach To Patent Eligibility, Law360, July 2017
- Shared Routes to Patent Eligibility, Daily Journal, December 2016
- USPTO Memo Leaves Eligibility Questions Unanswered, Law360, May 2016
- Divided Infringement Challenges for Personalized Medicine, Daily Journal, June 2015
- Burdens of Section 101 following Myriad, Daily Journal, October 2013
- Containing Myriad, The Recorder, August 2013
- Monoclonal Antibody Patents: Evolving Law & Strategies, Intellectual Property & Technology Law Journal, October 2012
- Human SOCS1 controls immunostimulatory activity of monocyte-derived dendritic cells, Cancer Research, 2009 Oct. 15;69(20):8076-84
- A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression, Nature Medicine, 2008 Mar.:14(3):258-265
- Dendritic cell-based tumor vaccines and antigen presentation attenuators, Molecular Therapy, 2006 May;13(5):850-8
- Inhibition of antigen presentation attenuators to augment vaccines, Current Opinion in Molecular Therapeutics, 2006 Feb.;8(1):24-30
- SOCS1 restricts dendritic cell's ability to break self-tolerance and induce anti-tumor immunity by controlling IL-12 production and signaling, Journal of Clinical Investigation, 2006 Jan.;116(1):90-100
- An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells, PLoS Medicine, 2006 Jan.:3(1)e11
- Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity, Nature Biotechnology, 2004 Dec.;22(12):1546-53